Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash & Current Investments (2016 - 2025)

Ultragenyx Pharmaceutical has reported Cash & Current Investments over the past 11 years, most recently at $680.0 million for Q4 2025.

  • Quarterly Cash & Current Investments rose 11.48% to $680.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $680.0 million through Dec 2025, up 11.48% year-over-year, with the annual reading at $680.0 million for FY2025, 11.48% up from the prior year.
  • Cash & Current Investments was $680.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $425.2 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $965.4 million in Q1 2021 and troughed at $412.1 million in Q1 2024.
  • The 5-year median for Cash & Current Investments is $615.8 million (2024), against an average of $638.1 million.
  • Year-over-year, Cash & Current Investments soared 151.98% in 2021 and then crashed 50.25% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $740.2 million in 2021, then grew by 1.02% to $747.8 million in 2022, then decreased by 22.75% to $577.6 million in 2023, then increased by 5.6% to $610.0 million in 2024, then increased by 11.48% to $680.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Cash & Current Investments are $680.0 million (Q4 2025), $425.2 million (Q3 2025), and $487.6 million (Q2 2025).